CURRICULUM VITAE - LARS E. BRATTSTRÖM

Born September 5, 1940

1964    Sea captain. Kalmar Maritime College, Sweden
1965    Officer in the Royal Swedish Navy Reserve (present rank: captain)
1966    Business school, Kalmar, Sweden
1967    Medical doctor, University of Lund, Sweden
1984    Fully qualified physician, University of Lund, Sweden
1988    Specialist of neurology, University of Lund, Sweden
1989    PhD, University of Lund, Sweden
1990    Associate professor of neurology, University of Lund, Sweden

1982        Neurological training: Department of Neurology, University Hospital, Lund, Sweden
1984-1988 Residency: Department of Neurology, University Hospital, Lund, Sweden
1989-1990 Consultant neurologist: Department of Neurology, University Hospital, Lund, Sweden
1991-                Senior cosultant neurologist: Section of Neurology, Department of Medicine, Kalmar Hospital, Kalmar, Sweden (present position)

I have been principal investigator in several clinical studies and have in conjunction with these been educated in GCP

1: Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM
Total homocysteine and cardiovascular disease.
J Intern Med. 1999 Nov;246(5):425-54. Review.
2: Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C.
Plasma total homocysteine and cysteine in relation to glomerular filtration rate
in diabetes mellitus.
Kidney Int. 1999 Mar;55(3):1028-35.
3: Brattstrom L, Zhang Y, Hurtig M, Refsum H, Ostensson S, Fransson L, Jones K,
Landgren F, Brudin L, Ueland PM.
A common methylenetetrahydrofolate reductase gene mutation and longevity.
Atherosclerosis. 1998 Dec;141(2):315-9.
4: Brattstrom L, Wilcken DE, Ohrvik J, Brudin L.
Common methylenetetrahydrofolate reductase gene mutation leads to
hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis.
Circulation. 1998 Dec 8;98(23):2520-6.
5: Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P,
Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I.
Low circulating folate and vitamin B6 concentrations: risk factors for stroke,
peripheral vascular disease, and coronary artery disease. European COMAC Group.
Circulation. 1998 Feb 10;97(5):437-43.
6: Brattstrom L.
Common mutation in the methylenetetrahydrofolate reductase gene offers no
support for mild hyperhomocysteinemia being a causal risk factor for
cardiovascular disease.
Circulation. 1997 Nov 18;96(10):3805-7. No abstract available.
7: Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al.
Plasma homocysteine as a risk factor for vascular disease. The European
Concerted Action Project.
JAMA. 1997 Jun 11;277(22):1775-81.
8: Nilsson K, Gustafson L, Faldt R, Andersson A, Brattstrom L, Lindgren A,
Israelsson B, Hultberg B.
Hyperhomocysteinaemia--a common finding in a psychogeriatric population.
Eur J Clin Invest. 1996 Oct;26(10):853-9.
9: Hultberg B, Isaksson A, Lindgren A, Israelsson B, Brattstrom L.
beta-Hexosaminidase isoenzymes A and B in middle-aged and elderly subjects:
determinants of plasma levels and relation to vascular disease.
Ann Clin Biochem. 1996 Sep;33 ( Pt 5):432-7.
10: Brattstrom L.
Vitamins as homocysteine-lowering agents.
J Nutr. 1996 Apr;126(4 Suppl):1276S-80S. Review.
11: Hultberg B, Isaksson A, Lindgren A, Israelsson B, Brattstrom L.
Plasma beta-hexosaminidase isoenzymes A and B in patients with cerebral
infarction.
Clin Chim Acta. 1996 Jan 15;244(1):35-44.
12: Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB.
Plasma homocysteine in the acute and convalescent phases after stroke.
Stroke. 1995 May;26(5):795-800.
13: Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L.
Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect
of folic acid.
J Intern Med. 1995 Apr;237(4):381-8.
14: Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B.
Homocysteine and cysteine: determinants of plasma levels in middle-aged and
elderly subjects.
J Intern Med. 1994 Dec;236(6):633-41.
15: Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Andersson A,
Nilsson-Ehle P.
The effect of high-dose pyridoxine and folic acid supplementation on serum lipid
and plasma homocysteine concentrations in dialysis patients.
Clin Nephrol. 1993 Oct;40(4):236-40.
16: Andersson A, Isaksson A, Brattstrom L, Hultberg B.
Homocysteine and other thiols determined in plasma by HPLC and thiol-specific
postcolumn derivatization.
Clin Chem. 1993 Aug;39(8):1590-7.
17: Israelsson B, Brattstrom L, Refsum H.
Homocysteine in frozen plasma samples. A short cut to establish
hyperhomocysteinaemia as a risk factor for arteriosclerosis?
Scand J Clin Lab Invest. 1993 Aug;53(5):465-9.
18: Hultberg B, Lindgren A, Brattstrom L, Isaksson A.
Elevated urinary beta-hexosaminidase in patients with stroke.
Scand J Clin Lab Invest. 1992 Dec;52(8):777-80.
19: Andersson A, Hultberg B, Brattstrom L, Isaksson A.
Decreased serum homocysteine in pregnancy.
Eur J Clin Chem Clin Biochem. 1992 Jun;30(6):377-9.
20: Brattstrom L, Israelsson B, Olsson A, Andersson A, Hultberg B.
Plasma homocysteine in women on oral oestrogen-containing contraceptives and in
men with oestrogen-treated prostatic carcinoma.
Scand J Clin Lab Invest. 1992 Jun;52(4):283-7.
21: Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B,
Hamfelt A.
Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of
stroke and stroke risk factors.
Eur J Clin Invest. 1992 Mar;22(3):214-21.
22: Hultberg B, Isaksson A, Brattstrom L, Israelsson B.
Elevated urinary excretion of beta-hexosaminidase in smokers.
Eur J Clin Chem Clin Biochem. 1992 Mar;30(3):131-3.
23: Brattstrom L, Israelsson B, Hultberg B.
[Hyperhomocysteinemia--a new risk factor for vascular diseases]?
Lakartidningen. 1992 Feb 12;89(7):467-9. Review. Swedish. No abstract available.
24: Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B.
Plasma homocysteine before and after methionine loading with regard to age,
gender, and menopausal status.
Eur J Clin Invest. 1992 Feb;22(2):79-87.
25: Brattstrom L, Lindgren A.
Hyperhomocysteinemia as a risk factor for stroke.
Neurol Res. 1992;14(2 Suppl):81-4. Review. No abstract available.
26: Ohlin H, Brattstrom L, Israelsson B, Bergqvist D, Jerntorp P.
Atherosclerosis and acetaldehyde metabolism in blood.
Biochem Med Metab Biol. 1991 Dec;46(3):317-28.
27: Andersson A, Isaksson A, Brattstrom L, Israelsson B, Hultberg B.
Influence of hydrolysis on plasma homocysteine determination in healthy subjects
and patients with myocardial infarction.
Atherosclerosis. 1991 Jun;88(2-3):143-51.
28: Hultberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelsson B,
Agardh CD.
Increased levels of plasma homocysteine are associated with nephropathy, but not
severe retinopathy in type 1 diabetes mellitus.
Scand J Clin Lab Invest. 1991 May;51(3):277-82.
29: Ohlin H, Jerntorp P, Brattstrom L, Almer LO, Israelsson B.
Altered metabolism of acetaldehyde in blood is not a specific marker of diabetic
macroangiopathy.
Diabetes Res. 1991 Feb;16(2):75-9.
30: Brattstrom L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B.
Plasma homocysteine in venous thromboembolism.
Haemostasis. 1991;21(1):51-7.
31: Brattstrom L, Stavenow L, Galvard H, Nilsson-Ehle P, Berntorp E, Jerntorp P,
Elmstahl S, Pessah-Rasmussen H.
Pyridoxine reduces cholesterol and low-density lipoprotein and increases
antithrombin III activity in 80-year-old men with low plasma pyridoxal
5-phosphate.
Scand J Clin Lab Invest. 1990 Dec;50(8):873-7.
32: Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hultberg B.
The effect of excess daily methionine intake on plasma homocysteine after a
methionine loading test in humans.
Clin Chim Acta. 1990 Nov 15;192(1):69-76.
33: Pessah-Rasmussen H, Jerntorp P, Stavenow L, Elmstahl S, Hansen F, Seidegard
J, Galvard H, Brattstrom L, Hamfelt A.
Eighty-year-old men without cardiovascular disease in the community of Malmo.
Part II. Smoking characteristics and ultrasound findings, with special reference
to glutathione transferase and pyridoxal-5-phosphate.
J Intern Med. 1990 Jul;228(1):17-22.
34: Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B,
Hamfelt A.
Impaired homocysteine metabolism in early-onset cerebral and peripheral
occlusive arterial disease. Effects of pyridoxine and folic acid treatment.
Atherosclerosis. 1990 Feb;81(1):51-60. Review.
35: Andersson A, Brattstrom L, Isaksson A, Israelsson B, Hultberg B.
Determination of homocysteine in plasma by ion-exchange chromatography.
Scand J Clin Lab Invest. 1989 Sep;49(5):445-9.
36: Brattstrom L, Israelsson B, Hultberg B.
Plasma homocysteine and methionine tolerance in early-onset vascular disease.
Haemostasis. 1989;19 Suppl 1:35-44. Review.
37: Brattstrom L, Israelsson B, Tengborn L, Hultberg B.
Homocysteine, factor VII and antithrombin III in subjects with different gene
dosage for cystathionine beta-synthase.
J Inherit Metab Dis. 1989;12(4):475-82.
38: Israelsson B, Brattstrom LE, Hultberg BL.
Homocysteine and myocardial infarction.
Atherosclerosis. 1988 Jun;71(2-3):227-33.
39: Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL.
Folic acid--an innocuous means to reduce plasma homocysteine.
Scand J Clin Lab Invest. 1988 May;48(3):215-21.
40: Brattstrom L, Israelsson B, Lindgarde F, Hultberg B.
Higher total plasma homocysteine in vitamin B12 deficiency than in
heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency.
Metabolism. 1988 Feb;37(2):175-8.
41: Brattstrom L, Englund E, Brun A.
Does Down syndrome support homocysteine theory of arteriosclerosis?
Lancet. 1987 Feb 14;1(8529):391-2. No abstract available.
42: Brattstrom LE, Hultberg BL, Hardebo JE.
Folic acid responsive postmenopausal homocysteinemia.
Metabolism. 1985 Nov;34(11):1073-7.
43: Brattstrom LE, Hardebo JE, Hultberg BL.
Moderate homocysteinemia--a possible risk factor for arteriosclerotic
cerebrovascular disease.
Stroke. 1984 Nov-Dec;15(6):1012-6.
44: Brattstrom L, Hindfelt B, Nilsson O.
Transient neurological symptoms associated with mononuclear pleocytosis of the
cerebrospinal fluid.
Acta Neurol Scand. 1984 Aug;70(2):104-10.
45: Brattstrom L.
Homocysteine and cerebral and peripheral vascular disease. In: Homocysteine metabolism from basic science to clinical medicine. (Graham I, Refsum H, Rosenberg IH, Ueland PM eds.), Kluwer Academic Publisher, Boston. 1997;199-204.
46: Graham I, Brattstrom L.
Homocysteinaemia and vascular disease. In: Advances in Thomas Addison´s diseases. (Bhatt HR, James VHT, Besser GM, Bottazzo GF, Keen H eds). J of Endocrin Ltd, Bristol. 1994;295-302.
48: Ueland PM, Brattstrom L, Refsum H.
Plasma homocysteine and cardiovascular disease. In: Atherosclerotic cardiovascular disease (Francis RB ed.). Marcel Dekker, New York. 1992;183-235.
49: Brattstrom L, Israelsson B, Hultberg B.
Impaired homocysteine metabolism - A possible  risk factor for arteriosclerotic vascular disease. In: Genetic susceptibility to environmenatal factors - a challange for public intervention (Smith U, Eriksson S, Lindgärde F eds.), Almqvist & Wiksell, Stockholm. 1988;25-34.
50: Nielsen NE, Brattstrom L, Hultberg B, Landgren F, Swan Eva.
Plasma homocysteine levels in postmenopausal women with unstable coronary artery disease. Atherosclerosis 2000:in press
51: Brattstrom L, Wilcken DEL.
Homocysteine and cardiovascular disease: cause or effect.
Am J Clin Nutr. 2000;in press

April 5^th, 2000

Lars Brattström